HRP20240120T1 - Nova farmaceutska formulacija koja sadrži dvojne antagoniste nk-1/nk-3 receptora - Google Patents
Nova farmaceutska formulacija koja sadrži dvojne antagoniste nk-1/nk-3 receptora Download PDFInfo
- Publication number
- HRP20240120T1 HRP20240120T1 HRP20240120TT HRP20240120T HRP20240120T1 HR P20240120 T1 HRP20240120 T1 HR P20240120T1 HR P20240120T T HRP20240120T T HR P20240120TT HR P20240120 T HRP20240120 T HR P20240120T HR P20240120 T1 HRP20240120 T1 HR P20240120T1
- Authority
- HR
- Croatia
- Prior art keywords
- soft gelatin
- gelatin capsule
- capsule formulation
- concentration
- formulation according
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title 1
- 102000002003 Neurokinin-3 Receptors Human genes 0.000 title 1
- 108010040716 Neurokinin-3 Receptors Proteins 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 21
- 239000007903 gelatin capsule Substances 0.000 claims 20
- 238000009472 formulation Methods 0.000 claims 18
- 229940126062 Compound A Drugs 0.000 claims 8
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 8
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 7
- 229920000053 polysorbate 80 Polymers 0.000 claims 7
- 229940068968 polysorbate 80 Drugs 0.000 claims 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical group OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 6
- 125000005456 glyceride group Chemical group 0.000 claims 6
- 208000024891 symptom Diseases 0.000 claims 6
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims 5
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims 5
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims 5
- 239000003963 antioxidant agent Substances 0.000 claims 3
- 230000003078 antioxidant effect Effects 0.000 claims 3
- 235000006708 antioxidants Nutrition 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003163 gonadal steroid hormone Substances 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 2
- 206010027566 Micturition urgency Diseases 0.000 claims 2
- 206010033307 Overweight Diseases 0.000 claims 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 2
- 210000000577 adipose tissue Anatomy 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 2
- 206010013990 dysuria Diseases 0.000 claims 2
- 239000003995 emulsifying agent Substances 0.000 claims 2
- 206010022437 insomnia Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 230000001457 vasomotor Effects 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 claims 1
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 230000009245 menopause Effects 0.000 claims 1
- 208000007106 menorrhagia Diseases 0.000 claims 1
- DWRIJNIPBUFCQS-DQEYMECFSA-N n-[6-[(7s,9as)-7-(hydroxymethyl)-3,4,6,7,9,9a-hexahydro-1h-pyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2[C@@H](CN3CCOC[C@@H]3C2)CO)C=C(C=2C(=CC(F)=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 DWRIJNIPBUFCQS-DQEYMECFSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000022925 sleep disturbance Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000010579 uterine corpus leiomyoma Diseases 0.000 claims 1
- 201000007954 uterine fibroid Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (18)
1. Formulacija meke želatinske kapsule, koja sadrži:
(a) 2-[3,5-Bis(trifluorometil)fenil]-N-{4-(4-fluoro-2-metilfenil)-6-[(7S,9aS)-7-(hidroksimetil)heksahidropirazino[2,1-c] [1,4]oksazin-8(1H)-il]-3-piridinil}-N,2-dimetilpropanamid (Spoj A):
[image]
ili njegovu farmaceutski prihvatljivu sol; i
(b) najmanje jedan solubilizator odabran između kaprilokaproil polioksil-8 glicerida, glicerol monokaprilokaprata, polioksil 35 ricinusovog ulja, polisorbata 80 ili njihovih smjesa.
2. Formulacija meke želatinske kapsule prema zahtjevu 1, naznačena time što nadalje sadrži antioksidant.
3. Formulacija meke želatinske kapsule prema zahtjevu 1 ili 2, naznačena time što nadalje sadrži emulgator.
4. Formulacija meke želatinske kapsule prema bilo kojem od zahtjeva 1-3, naznačena time što nadalje sadrži jedno ili više dodatnih terapijskih sredstava.
5. Formulacija meke želatinske kapsule prema bilo kojem od zahtjeva 1-4, naznačena time što je količina Spoja A u farmaceutskoj formulaciji u rasponu od 10 mg do 80 mg.
6. Formulacija meke želatinske kapsule prema bilo kojem od zahtjeva 1-5 , naznačena time što je solubilizator smjesa glicerol monokaprilokaprata kaprilokaproil polioksil-8 glicerida i polisorbata 80, pri čemu se koncentracija glicerol monokaprilokapratera kreće u rasponu od 30% m/m do 40% m/m, koncentracija kaprilokaproil polioksil-8 glicerida se kreće u rasponu od 9% m/m do 10% m/m, koncentracija polisorbata 80 se kreće u rasponu od 9% m/m do 10% m/m.
7. Formulacija meke želatinske kapsule prema bilo kojem od zahtjeva 3-6, naznačena time što je emulgator gliceril monooleat
8. Formulacija meke želatinske kapsule prema bilo kojem od zahtjeva 2-7, naznačena time što je antioksidant odabran između DL-alfa tokoferola (vitamin E), butiliranog hidroksitoluena (BHT) i butiliranog hidroksianizola (BHA) ili njihovih smjesa.
9. Formulacija meke želatinske kapsule prema bilo kojem od zahtjeva 2- 8, naznačena time što je antioksidant DL-alfa tokoferol (vitamin E) u koncentraciji u rasponu od 0,05% m/m do 1,5% m/m.
10. Formulacija meke želatinske kapsule prema bilo kojem od zahtjeva 1-9, naznačena time što sadrži spoj A, glicerol monokaprilokaprat, polisorbat 80, gliceril monooleat i DL-alfa tokoferol (vitamin E).
11. Formulacija meke želatinske kapsule prema bilo kojem od zahtjeva 1-10, naznačena time što sadrži spoj A, glicerol monokaprilokaprat, kaprilokaproil polioksil-8 gliceride, polisorbat 80, gliceril monooleat i DL-alfa tokoferol (vitamin E).
12. Formulacija meke želatinske kapsule prema bilo kojem od zahtjeva 1-11, naznačena time što sadrži:
(a) Spoj A od oko 1% m/m do oko 10% m/m;
(b1) glicerol monokaprilokaprat prisutan u koncentraciji u rasponu od 30% m/m do 40% m/m;
(b2) kaprilokaproil polioksil-8 gliceride prisutne u koncentraciji u rasponu od 7% m/m do 13% m/m;
(b3) Polisorbat 80 prisutan u koncentraciji od 7% m/m do 13% m/m
(c) gliceril monooleat prisutan u koncentraciji u rasponu od oko 33% m/m do 43% m/m; i
(d) DL-alfa tokoferol (vitamin E) prisutan u koncentraciji u rasponu od 0,05% m/m do 1,5% m/m.
13. Formulacija meke želatinske kapsule prema bilo kojem od zahtjeva 1-12, naznačena time što sadrži:
(a) Spoj A prisutan u koncentraciji od 5 % m/m;
(b1) glicerol monokaprilokaprat prisutan u koncentraciji od 37,05 % m/m;
(b2) kaprilokaproil polioksil-8 gliceride prisutne u koncentraciji od 9,5 % m/m;
(b3) Polisorbat 80 prisutan u koncentraciji od 9,5 % m/m;
(c) gliceril monooleat prisutan u koncentraciji od 38 % m/m; i
(d) DL-alfa tokoferol (vitamin E) prisutan u koncentraciji od 0,95 % m/m.
14. Formulacija meke želatinske kapsule prema zahtjevima 1-13, za upotrebu u liječenju ili prevenciji bolesti ovisne o spolnim hormonima, ili u liječenju ili prevenciji stanja, gdje je stanje simptom povezan s perimenopauzom, menopauza, ili postmenopauza odabrana od patološkog porasta prekomjerne tjelesne masti i/ili prekomjerne tjelesne težine, nesanice, poremećaja spavanja i noćnih buđenja, tjeskobe i depresije, simptoma hitnosti mokrenja i disurije; ili pri čemu je stanje simptom povezan s andropauzom odabran od patološkog porasta viška tjelesne masti i/ili prekomjerne tjelesne težine, nesanice, poremećaja spavanja i noćnih buđenja, anksioznosti i depresije, simptoma hitnosti mokrenja i disurije.
15. Formulacija meke želatinske kapsule za upotrebu prema zahtjevu 14, naznačena time što je bolest ovisna o spolnim hormonima odabrana između endometrioze, fibroidnog tumora maternice, teškog menstrualnog krvarenja, sindroma policističnih jajnika (PCOS) i vazomotornih simptoma.
16. Formulacija meke želatinske kapsule za upotrebu prema zahtjevu 14, naznačena time što je bolest ovisna o spolnim hormonima vazomotorni simptomi.
17. Postupak za proizvodnju meke želatinske kapsule, koji se sastoji od koraka osiguravanja ovojnice meke želatinske kapsule, miješanja formulacije meke želatinske kapsule koja sadrži spoj A ili njegove farmaceutski prihvatljive soli i najmanje jednu pomoćnu tvar, i ugradnje formulacije meke želatinske kapsule u želatinsku ovojnicu kapsule.
18. Postupak prema zahtjevu 17, naznačen time što je Spoj A u bezvodnom kristalnom obliku 1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862642622P | 2018-03-14 | 2018-03-14 | |
PCT/EP2019/056303 WO2019175253A1 (en) | 2018-03-14 | 2019-03-13 | Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists |
EP19711866.4A EP3765024B1 (en) | 2018-03-14 | 2019-03-13 | Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists. |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20240120T1 true HRP20240120T1 (hr) | 2024-04-12 |
Family
ID=65817992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20240120TT HRP20240120T1 (hr) | 2018-03-14 | 2019-03-13 | Nova farmaceutska formulacija koja sadrži dvojne antagoniste nk-1/nk-3 receptora |
Country Status (28)
Country | Link |
---|---|
US (5) | US10774091B2 (hr) |
EP (1) | EP3765024B1 (hr) |
JP (1) | JP7433252B2 (hr) |
KR (1) | KR20200139138A (hr) |
CN (1) | CN112292132A (hr) |
AU (1) | AU2019233606A1 (hr) |
BR (1) | BR112020017388A2 (hr) |
CA (1) | CA3092238A1 (hr) |
CL (1) | CL2020002350A1 (hr) |
CO (1) | CO2020011262A2 (hr) |
CR (1) | CR20200385A (hr) |
DK (1) | DK3765024T3 (hr) |
EA (1) | EA202092131A1 (hr) |
EC (1) | ECSP20057488A (hr) |
FI (1) | FI3765024T3 (hr) |
GE (1) | GEP20237503B (hr) |
HR (1) | HRP20240120T1 (hr) |
IL (1) | IL276959B1 (hr) |
JO (1) | JOP20200227A1 (hr) |
LT (1) | LT3765024T (hr) |
MA (1) | MA51999B1 (hr) |
MX (2) | MX2020009438A (hr) |
PE (1) | PE20210395A1 (hr) |
PH (1) | PH12020551457A1 (hr) |
PT (1) | PT3765024T (hr) |
RS (1) | RS65257B1 (hr) |
SG (1) | SG11202008226YA (hr) |
WO (1) | WO2019175253A1 (hr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017326611A1 (en) | 2016-09-18 | 2019-05-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | YAP1 inhibitors that target the interaction of YAP1 with Oct4 |
EP3765015A4 (en) | 2018-03-14 | 2021-12-15 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | YAP1 INHIBITORS AGAINST INTERACTION OF YAP1 WITH OCT4 |
EP3765024B1 (en) | 2018-03-14 | 2023-11-22 | KaNDy Therapeutics Limited | Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists. |
JP2023501666A (ja) | 2019-11-15 | 2023-01-18 | カンディー セラピューティクス リミテッド | Nt-814の重要な中間体である6-クロロ-4-(4-フルオロ-2-メチルフェニル)ピリジン-3-アミンを作製するための新規な化学的方法 |
KR102484687B1 (ko) * | 2022-03-04 | 2023-01-05 | (주)씨앤엘디 | 페노피브레이트를 포함하는 이상지질혈증의 예방 또는 치료용 약학 조성물 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3097618A (en) | 1960-12-01 | 1963-07-16 | Raymond Bag Corp | Manufacture of multi-wall bag having heat-sealed liner |
DE4322826A1 (de) * | 1993-07-08 | 1995-01-12 | Galenik Labor Freiburg Gmbh | Pharmazeutisches Präparat |
GB9907571D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Compounds |
AU7552401A (en) | 2000-06-12 | 2001-12-24 | Univ Rochester | Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist |
EP1192952A3 (en) | 2000-09-28 | 2003-03-26 | Pfizer Products Inc. | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist |
WO2002089802A2 (en) | 2001-05-08 | 2002-11-14 | Schering Corporation | Use of neurokinin receptor antagonists to treat androgen-dependent diseases |
JO2696B1 (en) | 2002-12-23 | 2013-03-03 | شركة جانسين فارماسوتيكا ان. في | Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists |
WO2004056805A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists |
US7525659B2 (en) | 2003-01-15 | 2009-04-28 | Negevtech Ltd. | System for detection of water defects |
CA2530886C (en) | 2003-07-03 | 2013-05-28 | F. Hoffmann-La Roche Ag | Dual nk1/nk3 antagonists for treating schizophrenia |
JO2676B1 (en) | 2004-04-06 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines |
JO2525B1 (en) | 2004-04-08 | 2010-03-17 | شركة جانسين فارماسوتيكا ان. في | Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin |
EP1748984A1 (en) | 2004-05-12 | 2007-02-07 | Pfizer Products Inc. | Piperidine derivatives as nk1 and nk3 antagonists |
DE102004033902A1 (de) | 2004-07-14 | 2006-02-16 | Zentaris Gmbh | Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's) |
WO2006013205A1 (en) | 2004-08-04 | 2006-02-09 | Solvay Pharmaceuticals B.V. | Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation |
US20060030600A1 (en) | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
EP1928886B1 (en) * | 2005-09-09 | 2011-04-13 | GlaxoSmithKline LLC | Pyridine derivatives and their use in the treatment of psychotic disorders |
AU2008240804B2 (en) | 2007-04-20 | 2013-02-21 | F. Hoffmann-La Roche Ag | Pyrrolidine derivatives as dual NK1/NK3 receptor antagonists |
GB0814340D0 (en) | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
CA2772168C (en) * | 2009-08-27 | 2019-01-08 | Glaxosmithkline Llc | Anhydrate forms of a pyridine derivative |
US8487102B2 (en) | 2010-04-20 | 2013-07-16 | Hoffmann-La Roche Inc. | Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists |
US9446029B2 (en) | 2010-07-27 | 2016-09-20 | Colorado State University Research Foundation | Use of NK-1 receptor antagonists in management of visceral pain |
ES2376564B1 (es) | 2010-08-12 | 2013-01-24 | Manuel Vicente Salinas Martín | Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer. |
GB2488788B (en) * | 2011-03-07 | 2013-07-10 | Natco Pharma Ltd | Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response |
KR20140097518A (ko) | 2011-12-02 | 2014-08-06 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 펩티드 데포르밀라제 억제제 |
KR101739820B1 (ko) | 2012-03-28 | 2017-05-25 | 주식회사유한양행 | 레바프라잔 또는 그의 염을 함유하는 비수성 액체 형태의 경구투여용 약학 조성물 |
WO2014089019A1 (en) | 2012-12-03 | 2014-06-12 | University Of Washington Through Its Center For Commercialization | Methods and compositions for treating vasomotor symptoms |
GB201315846D0 (en) | 2013-09-05 | 2013-10-23 | Imp Innovations Ltd | Method for treating or preventing hot flushes |
WO2016184829A1 (en) * | 2015-05-18 | 2016-11-24 | Nerre Therapeutics Limited | Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases |
EP3765024B1 (en) | 2018-03-14 | 2023-11-22 | KaNDy Therapeutics Limited | Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists. |
JP2023501666A (ja) | 2019-11-15 | 2023-01-18 | カンディー セラピューティクス リミテッド | Nt-814の重要な中間体である6-クロロ-4-(4-フルオロ-2-メチルフェニル)ピリジン-3-アミンを作製するための新規な化学的方法 |
-
2019
- 2019-03-13 EP EP19711866.4A patent/EP3765024B1/en active Active
- 2019-03-13 RS RS20240167A patent/RS65257B1/sr unknown
- 2019-03-13 GE GEAP201915464A patent/GEP20237503B/en unknown
- 2019-03-13 FI FIEP19711866.4T patent/FI3765024T3/fi active
- 2019-03-13 BR BR112020017388-6A patent/BR112020017388A2/pt unknown
- 2019-03-13 DK DK19711866.4T patent/DK3765024T3/da active
- 2019-03-13 MA MA51999A patent/MA51999B1/fr unknown
- 2019-03-13 IL IL276959A patent/IL276959B1/en unknown
- 2019-03-13 EA EA202092131A patent/EA202092131A1/ru unknown
- 2019-03-13 WO PCT/EP2019/056303 patent/WO2019175253A1/en active Application Filing
- 2019-03-13 HR HRP20240120TT patent/HRP20240120T1/hr unknown
- 2019-03-13 MX MX2020009438A patent/MX2020009438A/es unknown
- 2019-03-13 LT LTEPPCT/EP2019/056303T patent/LT3765024T/lt unknown
- 2019-03-13 AU AU2019233606A patent/AU2019233606A1/en active Pending
- 2019-03-13 JP JP2020572615A patent/JP7433252B2/ja active Active
- 2019-03-13 KR KR1020207026436A patent/KR20200139138A/ko unknown
- 2019-03-13 JO JOP/2020/0227A patent/JOP20200227A1/ar unknown
- 2019-03-13 CN CN201980019147.6A patent/CN112292132A/zh active Pending
- 2019-03-13 US US16/351,659 patent/US10774091B2/en active Active
- 2019-03-13 PE PE2020001406A patent/PE20210395A1/es unknown
- 2019-03-13 PT PT197118664T patent/PT3765024T/pt unknown
- 2019-03-13 SG SG11202008226YA patent/SG11202008226YA/en unknown
- 2019-03-13 CR CR20200385A patent/CR20200385A/es unknown
- 2019-03-13 CA CA3092238A patent/CA3092238A1/en active Pending
-
2020
- 2020-08-04 US US16/984,961 patent/US11591346B2/en active Active
- 2020-08-04 US US16/985,087 patent/US11787820B2/en active Active
- 2020-09-10 MX MX2022005706A patent/MX2022005706A/es unknown
- 2020-09-11 CO CONC2020/0011262A patent/CO2020011262A2/es unknown
- 2020-09-11 CL CL2020002350A patent/CL2020002350A1/es unknown
- 2020-09-11 PH PH12020551457A patent/PH12020551457A1/en unknown
- 2020-09-14 EC ECSENADI202057488A patent/ECSP20057488A/es unknown
-
2023
- 2023-01-13 US US18/097,046 patent/US11767328B2/en active Active
- 2023-07-31 US US18/228,593 patent/US20230382922A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20240120T1 (hr) | Nova farmaceutska formulacija koja sadrži dvojne antagoniste nk-1/nk-3 receptora | |
JP5836322B2 (ja) | ステロールによる親油性薬剤の溶解性、安定性、吸収性、代謝性、及び薬物動態プロファイルの調節 | |
US10973833B2 (en) | High-strength testosterone undecanoate compositions | |
JP2023123442A (ja) | 持続性抑制を増加させ、二次性不眠症を治療する方法 | |
JP2015520237A5 (hr) | ||
DK2349250T3 (en) | Fatty acids for use as a medicament | |
US20120148675A1 (en) | Testosterone undecanoate compositions | |
WO2017173185A1 (en) | Steroid hormone pharmaceutical composition | |
US20130281523A1 (en) | Low dose cannabinoid medicaments | |
CA2929321A1 (en) | Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders | |
US9358241B2 (en) | High-strength testosterone undecanoate compositions | |
AU2014340710B2 (en) | Compressed tablet containing delta 9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment | |
JP2008536851A (ja) | 女性でテストステロンおよび関連ステロイドの濃度を増加させる方法 | |
JP2023537240A (ja) | 19-ノルc3,3-二置換c21-n-ピラゾリルステロイドの製剤及びその使用方法 | |
TW201444586A (zh) | 乳液調配物 | |
JP2023537840A (ja) | ナビロンを単独及びカンナビノイドと併用する経皮製剤 | |
TW201431569A (zh) | 具有高含量菲索芬那定(fexofenadine)之固態單位及其製備方法 | |
US11433083B2 (en) | High-strength testosterone undecanoate compositions | |
JP7309824B2 (ja) | 不安障害を治療するための(2S)-1-[4-(3,4-ジクロロフェニル)ピペリジン-1-イル]-3-[2-(5-メチル-1,3,4-オキサジアゾール-2-イル)ベンゾ[b]フラン-4-イルオキシ]プロパン-2-オールまたはその代謝産物 | |
RU2722592C2 (ru) | Длинноцепочечные липосбалансированные сложные эфиры тестостерона для пероральной доставки | |
CA3181084A1 (en) | Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia | |
JP2001131057A (ja) | 鼻粘膜付着マトリックス | |
US20240173335A1 (en) | Oral Allopregnanolone Compositions and Methods of Use | |
KR102125740B1 (ko) | 텍토리게닌 7-0-자일로실글루코시드를 포함하는 여성 갱년기 증상 완화용 조성물 | |
TWI835716B (zh) | 治療良性前列腺增殖徵候與症狀之四氫環戊[b]吲哚化合物與磷酸二酯酶抑制劑 |